Loading
A phase 3 trial of Daratumumab, Carfilzomib, Dexamethasone in multiple myeloma, run by Janssen Research & Development, LLC, active and no longer recruiting.
A Study of Daratumumab is a phase 3 interventional study registered as NCT05438043 by Janssen Research & Development, LLC, with 213 participants enrolled, started 2022-12-15 and due to reach its primary completion in 2029-01-31. Interventions recorded: Daratumumab, Carfilzomib, Dexamethasone, Lenalidomide, Pomalidomide. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.
Shares Daratumumab, Lenalidomide, Dexamethasone, Johnson & Johnson.
Shares Pomalidomide, Daratumumab, Dexamethasone, Multiple myeloma.
Shares Pomalidomide, Daratumumab, Dexamethasone, Johnson & Johnson.
Shares Carfilzomib, Pomalidomide, Daratumumab, Dexamethasone.
Shares Daratumumab, Lenalidomide, Dexamethasone, Johnson & Johnson.
Shares Carfilzomib, Daratumumab, Lenalidomide, Dexamethasone.
Shares Carfilzomib, Pomalidomide, Daratumumab, Dexamethasone.
Shares Pomalidomide, Daratumumab, Lenalidomide, Dexamethasone.